Our Focus

Focused on Improving Treatment Options

Synspira Therapeutics is initially focused on cystic fibrosis and others with rare diseases (primary ciliary dyskinesia, bronchiectasis) who suffer progressive pulmonary disease or life-threatening rare pulmonary conditions.

Synspira’s innovative and proprietary glycochemistry technology platform for inhaled therapeutics is designed to target and change the course of life-threatening progressive pulmonary diseases.

Synspira Therapeutics is committed to providing simple product solutions to improve the long-term health of people with CF and other rare disease indications. Learn more here. 

Our Lead Product: SNSP113

SNSP113 is a first-in-class product with a broad spectrum mechanism of action. SNSP113 is designed to target the underlying cascade of events that lead to progressive pulmonary disease or other life-threatening pulmonary conditions.

SNSP113 offers unique advantages due to its novel mechanism of action by providing a broad spectrum treatment for the key drivers of pulmonary decline in cystic fibrosis and others with progressive pulmonary diseases including life-threatening pulmonary infections such as nontuberculous Mycobacteria (NTM), Burkholderia cepacia complex (BCC), Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus (MRSA).

SNSP113 is developed to:

  1. Interact with the cell walls of invading bacteria to increase their permeability, reduce their viability, and potentiate the efficacy of antibiotics.
  2. Disrupt the cohesion of bacterial biofilms to reduce chronic antibiotic resistance.
  3. Normalize mucin viscosity and improve mucus transport thereby increasing airway clearance.
  4. Reduce the inflammatory cascade of neutrophils that can lead to tissue damage and fibrosis.

SNSP113 is designed to reduce infection, airway congestion and inflammation–the key drivers of pulmonary exacerbations and pulmonary decline in cystic fibrosis patients.

The company is evaluating SNSP113 for cystic fibrosis and other rare diseases as well as those individuals affected with life-threatening pulmonary conditions. SNSP113 is entering Phase 2 clinical trials in cystic fibrosis (CF).